SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--
Regulatory News:
Median Technologies (Paris:ALMDT):
Total number of shares |
18,418,233 |
Number of real voting rights* (excluding treasury shares**) |
18,373,987 |
Theoretical number of voting rights* (including treasury shares**) |
18,352,941 |
(*) Class E preference shares are non-voting
(**) pursuant to article 223-11 of the AMF’s General Regulations
About Median Technologies: Pioneering in innovative imaging solutions and services, Median Technologies harnesses cutting-edge AI to elevate the accuracy of early cancer diagnoses and cancer treatments. Median's offerings, including iCRO for medical image analysis and management in oncology trials and eyonis™, AI/ML tech-based suite of software as medical devices (SaMD), empower biopharmaceutical entities and clinicians to advance patient care and expedite novel therapies. The French-based company, with a presence in the U.S. and China, is listed on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is eligible for the French SME equity savings plan scheme (PEA-PME). For more information:
View source version on businesswire.com:
